Novartis announced two positive Phase 3 trial readouts for ianalumab, a monoclonal antibody with dual B-cell depletion and BAFF-R inhibition activities, in Sjögren’s disease and primary immune thrombocytopenia (ITP). These represent the first registrational studies demonstrating statistically significant efficacy in Sjögren’s and improved durable platelet maintenance in ITP when combined with eltrombopag. The data underline ianalumab’s potential as a novel treatment for challenging autoimmune disorders lacking approved therapies, advancing Novartis’ immunology portfolio and paving the way for regulatory submissions.